Abstract

Although therapeutic strategies have been adapted to age and comorbidities for a long time, almost all multiple myeloma (MM) patients currently receive similar treatment, whatever their disease risk category. However, high-risk MM patients still constitute an unmet medical need and should benefit from the most efficient drug combinations. Herein, we review and discuss how to optimally define risk and why a revision of the current definition is urgently needed.

REFERENCES

REFERENCES
1.
Chng
WJ
,
Dispenzieri
A
,
Chim
CS
, et al;
International Myeloma Working Group
.
IMWG consensus on risk stratification in multiple myeloma
.
Leukemia
.
2014
;
28
(
2
):
269
-
277
.
2.
Pawlyn
C
,
Cairns
D
,
Kaiser
M
, et al
.
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
.
Leukemia
.
2020
;
34
(
2
):
604
-
612
.
3.
Palumbo
A
,
Anderson
K
.
Multiple myeloma
.
N Engl J Med
.
2011
;
364
(
11
):
1046
-
1060
.
4.
Kumar
SK
,
Gertz
MA
.
Risk adapted therapy for multiple myeloma: back to basics
.
Leuk Lymphoma
.
2014
;
55
(
10
):
2219
-
2220
.
5.
Mikhael
JR
,
Dingli
D
,
Roy
V
, et al;
Mayo Clinic
.
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 [published correction appears in Mayo Clin Proc. 2013;88(7):777]
.
Mayo Clin Proc
.
2013
;
88
(
4
):
360
-
376
.
6.
Avet-Loiseau
H
.
Ultra high-risk myeloma
.
Hematology (Am Soc Hematol Educ Program)
.
2010
;
2010
:
489
-
493
.
7.
Usmani
SZ
,
Heuck
C
,
Mitchell
A
, et al
.
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
.
Haematologica
.
2012
;
97
(
11
):
1761
-
1767
.
8.
Bladé
J
,
de Larrea
CF
,
Rosiñol
L
.
Extramedullary involvement in multiple myeloma
.
Haematologica
.
2012
;
97
(
11
):
1618
-
1619
.
9.
Corre
J
,
Munshi
N
,
Avet-Loiseau
H
.
Genetics of multiple myeloma: another heterogeneity level?
Blood
.
2015
;
125
(
12
):
1870
-
1876
.
10.
Robiou du Pont
S
,
Cleynen
A
,
Fontan
C
, et al
.
Genomics of multiple myeloma
.
J Clin Oncol
.
2017
;
35
(
9
):
963
-
967
.
11.
Manier
S
,
Salem
KZ
,
Park
J
,
Landau
DA
,
Getz
G
,
Ghobrial
IM
.
Genomic complexity of multiple myeloma and its clinical implications
.
Nat Rev Clin Oncol
.
2017
;
14
(
2
):
100
-
113
.
12.
Chretien
ML
,
Corre
J
,
Lauwers-Cances
V
, et al
.
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
Blood
.
2015
;
126
(
25
):
2713
-
2719
.
13.
Kumar
S
,
Kaufman
JL
,
Gasparetto
C
, et al
.
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
.
Blood
.
2017
;
130
(
22
):
2401
-
2409
.
14.
Cleynen
A
,
Samur
M
,
Perrot
A
, et al
.
Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14)
.
Blood
.
2018
;
132
(
26
):
2778
-
2780
.
15.
Touzeau
C
,
Maciag
P
,
Amiot
M
,
Moreau
P
.
Targeting Bcl-2 for the treatment of multiple myeloma
.
Leukemia
.
2018
;
32
(
9
):
1899
-
1907
.
16.
Hebraud
B
,
Magrangeas
F
,
Cleynen
A
, et al
.
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience
.
Blood
.
2015
;
125
(
13
):
2095
-
2100
.
17.
San Miguel
JF
,
Schlag
R
,
Khuageva
NK
, et al;
VISTA Trial Investigators
.
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
.
N Engl J Med
.
2008
;
359
(
9
):
906
-
917
.
18.
Avet-Loiseau
H
,
Leleu
X
,
Roussel
M
, et al
.
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)
.
J Clin Oncol
.
2010
;
28
(
30
):
4630
-
4634
.
19.
Du
C
,
Mao
X
,
Xu
Y
, et al
.
1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib
.
Leuk Lymphoma
.
2020
;
61
(
5
):
1201
-
1210
.
20.
Avet-Loiseau
H
,
Malard
F
,
Campion
L
, et al;
Intergroupe Francophone du Myélome
.
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
Blood
.
2011
;
117
(
6
):
2009
-
2011
.
21.
Goldman-Mazur
S
,
Jurczyszyn
A
,
Castillo
JJ
, et al
.
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
.
Am J Hematol
.
2020
;
95
(
5
):
503
-
509
.
22.
Palumbo
A
,
Avet-Loiseau
H
,
Oliva
S
, et al
.
Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group
.
J Clin Oncol
.
2015
;
33
(
26
):
2863
-
2869
.
23.
Walker
BA
,
Mavrommatis
K
,
Wardell
CP
, et al
.
A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis
.
Leukemia
.
2019
;
33
(
1
):
159
-
170
.
24.
Schmidt
TM
,
Barwick
BG
,
Joseph
N
, et al
.
Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
.
Blood Cancer J
.
2019
;
9
(
12
):
94
.
25.
Hebraud
B
,
Leleu
X
,
Lauwers-Cances
V
, et al
.
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients [published correction appears in Leukemia. 2014;28(3):726]
.
Leukemia
.
2014
;
28
(
3
):
675
-
679
.
26.
Avet-Loiseau
H
,
Attal
M
,
Moreau
P
, et al
.
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
.
Blood
.
2007
;
109
(
8
):
3489
-
3495
.
27.
Thakurta
A
,
Ortiz
M
,
Blecua
P
, et al
.
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma
.
Blood
.
2019
;
133
(
11
):
1217
-
1221
.
28.
Dicker
F
,
Herholz
H
,
Schnittger
S
, et al
.
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype
.
Leukemia
.
2009
;
23
(
1
):
117
-
124
.
29.
Corre
J
,
Perrot
A
,
Caillot
D
, et al
.
Del17p without TP53 mutation confers poor prognosis in intensively treated newly diagnosed multiple myeloma patients
.
Blood
. In press.
30.
Chin
M
,
Sive
JI
,
Allen
C
, et al
.
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
.
Blood Cancer J
.
2017
;
7
(
9
):
e610
.
31.
Samur
MK
,
Samur
AA
,
Fulciniti
M
, et al
.
Genome wide somatic alterations in multiple myeloma reveals a superior outcome group
.
J Clin Oncol
.
2020
;
38
(
27
):
3107
-
3118
.
32.
Greipp
PR
,
San Miguel
J
,
Durie
BG
, et al
.
International staging system for multiple myeloma [published correction appears in J Clin Oncol. 2005;23(25):6281]
.
J Clin Oncol
.
2005
;
23
(
15
):
3412
-
3420
.
33.
Perrot
A
,
Lauwers-Cances
V
,
Tournay
E
, et al
.
Development and validation of a Cytogenetic prognostic index predicting survival in multiple myeloma
.
J Clin Oncol
.
2019
;
37
(
19
):
1657
-
1665
.
34.
Bolli
N
,
Li
Y
,
Sathiaseelan
V
, et al
.
A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma
.
Blood Cancer J
.
2016
;
6
(
9
):
e467
.
35.
Corre
J
,
Montes
L
,
Martin
E
, et al
.
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk [published online ahead of print 12 Dec 2019]
.
Haematologica
.
36.
Durie
BG
,
Jacobson
J
,
Barlogie
B
,
Crowley
J
.
Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials
.
J Clin Oncol
.
2004
;
22
(
10
):
1857
-
1863
.
37.
Kumar
S
,
Mahmood
ST
,
Lacy
MQ
, et al
.
Impact of early relapse after auto-SCT for multiple myeloma
.
Bone Marrow Transplant
.
2008
;
42
(
6
):
413
-
420
.
38.
Bal
S
,
Weaver
A
,
Cornell
RF
,
Costa
LJ
.
Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma
.
Br J Haematol
.
2019
;
186
(
6
):
807
-
819
.
39.
Perrot
A
,
Lauwers-Cances
V
,
Corre
J
, et al
.
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
.
Blood
.
2018
;
132
(
23
):
2456
-
2464
.
40.
Paiva
B
,
Puig
N
,
Cedena
MT
, et al;
GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group
.
Measurable residual disease by next-generation flow cytometry in multiple myeloma
.
J Clin Oncol
.
2020
;
38
(
8
):
784
-
792
.
You do not currently have access to this content.

Sign in via your Institution

Sign In